Eric Josiah Tan

Eric Josiah Tan

Auto-generated profile, based on publicly available information

Eric Josiah Tan

Centre for Mental Health and Brain Sciences, School of Health Sciences, Swinburne University of Technology

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in International Journal of Eating Disorders
Verified
Journal Article
Closed access
PDF file
APAndrea Phillipou
Andrea Phillipou
DMDenny Meyer
Denny Meyer
ENErica Neill
Erica Neill
ETEric J. Tan
Eric J. Tan
WTWei Lin Toh
Wei Lin Toh
SRSusan L. Rossell
Susan L. Rossell

28 February 2017 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
TRT. E. Van Rheenen
T. E. Van Rheenen
KLKathryn Eve Lewandowski
Kathryn Eve Lewandowski
ETE. J. Tan
E. J. Tan
LOL. H. Ospina
L. H. Ospina
DOD. Ongur
D. Ongur
KBK. E. Burdick
K. E. Burdick
Background: Current group-average analysis suggests quantitative but not qualitative cognitive differences between schizophrenia (SZ) and bipolar disorder (BD). There is increasing recognition that cognitive within-group heterogeneity exists in both disorders, but it remains unclear as to whether between-group comparisons of performance in cognitive subgroups emerging from within each of these nosological categories uphold group-average findings. We addressed this by identifying cognitive subgroups in large samples of SZ and BD patients independently, and comparing their cognitive profiles. The utility of a cross-diagnostic clustering approach to understanding cognitive heterogeneity in these patients was also explored.Method: Hierarchical clustering analyses were conducted using cognitive data from 1541 participants (SZn= 564, BDn= 402, healthy controln= 575).Results: Three qualitatively and quantitatively similar clusters emerged within each clinical group: a severely impaired cluster, a mild-moderately impaired cluster and a relatively intact cognitive cluster. A cross-diagnostic clustering solution also resulted in three subgroups and was superior in reducing cognitive heterogeneity compared with disorder clustering independently.Conclusions: Quantitative SZ–BD cognitive differences commonly seen using group averages did not hold when cognitive heterogeneity was factored into our sample. Members of each corresponding subgroup, irrespective of diagnosis, might be manifesting the outcome of differences in shared cognitive risk factors.

11 December 2019 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
CYCaitlin Ob Yolland
Caitlin Ob Yolland
DHDonal Hanratty
Donal Hanratty
ENErica Neill
Erica Neill
SRSusan L Rossell
Susan L Rossell
MBMichael Berk
Michael Berk
DSDan Siskind
Dan Siskind
There is accumulating evidence that adjunctive treatment with N-acetylcysteine may be effective for schizophrenia. This study aimed to conduct a comprehensive meta-analysis examining the efficacy of randomised control trials investigating N-acetylcysteine as an adjunct treatment for schizophrenia and the first to investigate cognition as an outcome. We systematically reviewed Medline, EmCare, PsycINFO, Embase, CINAHL Complete, China Knowledge Resource Integrated Database and the Cochrane Clinical Trials online registry for randomised control trials of N-acetylcysteine for schizophrenia. We undertook pairwise meta-analyses of N-acetylcysteine vs placebo for psychosis symptoms and cognition. Seven studies, including n = 220 receiving N-acetylcysteine and n = 220 receiving placebo, met inclusion criteria for the pairwise meta-analyses. Positive and Negative Syndrome Scale negative and total scores were significantly improved in the N-acetylcysteine group after 24 weeks of treatment. The cognitive domain of working memory improved with N-acetylcysteine supplementation. Evidence supports the notion that N-acetylcysteine may be a useful adjunct to standard treatment for the improvement of schizophrenia symptoms, as well as the cognitive domain of working memory. Treatment effects were observed at the later time point (⩾24 weeks), suggesting that longer interventions are required for the success of N-acetylcysteine treatment.


22 November 2018 in Journal of the International Neuropsychological Society
Verified
Journal Article
Closed access
PDF file
JBJulia Brodski
Julia Brodski
SRSusan L. Rossell
Susan L. Rossell
DCDavid J. Castle
David J. Castle
ETEric J. Tan
Eric J. Tan
Objectives: Recognition of cognitive impairment in chronic kidney disease (CKD) and its impact on functioning in adults is growing. The vast majority of studies to date have been conducted in older populations where CKD is more pronounced; however, the degree to which age-related cognitive changes could be influencing these findings remains unaddressed. This current study thus aimed to review cognitive impairment findings by stage in non-elderly CKD samples. Methods: PubMed and Medline via Scopus were searched for cross-sectional or cohort studies and randomized controlled trials that assessed cognitive function in individuals with CKD in any research setting. CKD studies including patients at any illness stage were included providing participants were below 65 years old, were not on peritoneal dialysis and had not undergone a kidney transplant. Results: Fifteen studies, with a total of 9304 participants, were included. Cognitive function broadly deteriorated from stage 1 to stage 5. Early stage CKD was associated with a drop in speed of processing, attention, response speed, and short-term memory abilities. Moderate stage CKD was associated with deficits in executive functioning, verbal fluency, logical memory, orientation and concentration. People with end stage kidney disease manifested significant deficits in all previous cognitive domains, along with cognitive control, delayed and immediate memory, visuospatial impairment, and overall cognitive impairment. Conclusions: Cognitive impairment is evident across the stages of CKD, independent of age-related changes, for both lower-order and higher-order cognitive abilities. These impairments also increase between the stages, suggesting a cumulative effect. Future directions for research are discussed. (JINS, 2019, 25, 101–114)

3 August 2020 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
ETEric J Tan
Eric J Tan
DMDenny Meyer
Denny Meyer
ENErica Neill
Erica Neill
APAndrea Phillipou
Andrea Phillipou
WTWei Lin Toh
Wei Lin Toh
SRSusan L Rossell
Susan L Rossell
During this unprecedented novel coronavirus (COVID-19) pandemic, there is an urgent need for empirical data to characterise its impact on the mental health and well-being of Australians. In this viewpoint, we outline a number of considerations for research on this topic, highlighting areas necessitating special attention, consideration of particular vulnerable groups and the need for longitudinal studies to track mental health fluctuations in the general population. We conclude by introducing the COLLATE (COvid-19 and you: mentaL heaLth in AusTralia now survEy) project, outlining its aims, addressing some considerations raised herein and detailing avenues for future research. Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 (WHO, 2020), the COVID-19 pandemic has caused major upheaval both in Australia and globally. While the search for a vaccine continues, current efforts towards tackling the virus and limiting contagion in several nations have focused on social distancing and the shutdown of non-essential services. In Australia, the first case was reported on 13 January 2020 (COVID-19 National Incident Room Surveillance Team, 2020), the first death occurred on 24 February and a spate of progressive restrictions were enforced throughout the 2 weeks leading up to 31 March 2020 (COVID-19 National Incident Room Surveillance Team, 2020a).